Podocytopathy in diabetes: a metabolic and endocrine disorder.
Authors Diez-Sampedro A, Lenz O, Fornoni A
Submitted By Alessia Fornoni on 12/10/2012
Status Published
Journal American journal of kidney diseases : the official journal of the National Kidney Foundation
Year 2011
Date Published 10/1/2011
Volume : Pages 58 : 637 - 646
PubMed Reference 21719174
Abstract Diabetic nephropathy (DN) represents a major public health cost. Tight glycemic
and blood pressure control can dramatically slow, but not stop, the progression
of the disease, and a large number of patients progress toward end-stage renal
disease despite currently available interventions. An early and key event in the
development of DN is loss of podocyte function (or glomerular visceral
epithelial cells) from the kidney glomerulus, where they contribute to the
integrity of the glomerular filtration barrier. Recent evidence suggests that
podocytes can be the direct target of circulating hormones, lipids, and
adipokines that are affected in diabetes. We review the clinical and
experimental evidence implicating novel endocrine and metabolic pathways in the
pathogenesis of podocyte dysfunction and the development of DN.

Investigators with authorship
Alessia FornoniUniversity of Miami - Medical Campus